Safety Study Evaluating the Adrenal Suppression Potential of Product 0405 in Pediatric Subjects With Atopic Dermatitis

NCT01232543 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

114

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Product 0405

Sponsor

Fougera Pharmaceuticals Inc.